IS8669A - Rasagilínlyfjablöndur sem einsleitni innihaldsefna hefur verið endurbætt í - Google Patents

Rasagilínlyfjablöndur sem einsleitni innihaldsefna hefur verið endurbætt í

Info

Publication number
IS8669A
IS8669A IS8669A IS8669A IS8669A IS 8669 A IS8669 A IS 8669A IS 8669 A IS8669 A IS 8669A IS 8669 A IS8669 A IS 8669A IS 8669 A IS8669 A IS 8669A
Authority
IS
Iceland
Prior art keywords
homogeneity
ingredients
improved
rasagiline formulations
rasagiline
Prior art date
Application number
IS8669A
Other languages
English (en)
Inventor
Berger Peskin Tirtza
Original Assignee
Teva Pharmaceutical Industries, Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36927751&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IS8669(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Pharmaceutical Industries, Ltd. filed Critical Teva Pharmaceutical Industries, Ltd.
Publication of IS8669A publication Critical patent/IS8669A/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IS8669A 2005-02-23 2007-08-15 Rasagilínlyfjablöndur sem einsleitni innihaldsefna hefur verið endurbætt í IS8669A (is)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US65562205P 2005-02-23 2005-02-23
US72090805P 2005-09-27 2005-09-27
PCT/US2006/006252 WO2006091657A1 (en) 2005-02-23 2006-02-22 Rasagiline formulations of improved content uniformity

Publications (1)

Publication Number Publication Date
IS8669A true IS8669A (is) 2007-08-15

Family

ID=36927751

Family Applications (1)

Application Number Title Priority Date Filing Date
IS8669A IS8669A (is) 2005-02-23 2007-08-15 Rasagilínlyfjablöndur sem einsleitni innihaldsefna hefur verið endurbætt í

Country Status (16)

Country Link
US (1) US7815942B2 (is)
EP (1) EP1848402B2 (is)
JP (2) JP5738509B2 (is)
KR (5) KR20070111534A (is)
AU (1) AU2006216696B2 (is)
BR (1) BRPI0608209A2 (is)
CA (2) CA2901244A1 (is)
ES (1) ES2586412T5 (is)
HK (1) HK1103366A1 (is)
IL (2) IL184033A0 (is)
IS (1) IS8669A (is)
MX (1) MX2007010233A (is)
NO (1) NO20074823L (is)
NZ (1) NZ560660A (is)
RU (1) RU2404746C2 (is)
WO (1) WO2006091657A1 (is)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744500A (en) * 1990-01-03 1998-04-28 Teva Pharmaceutical Industries, Ltd. Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
EP2526944B1 (en) 2002-11-15 2016-06-01 Teva Pharmaceutical Industries Limited Use of rasagiline with or without riluzole to treat amyotrophic lateral sclerosis
JP2008507586A (ja) * 2004-07-26 2008-03-13 テバ ファーマシューティカル インダストリーズ リミティド ラサグリンを含む、医薬投与剤
ZA200704917B (en) * 2004-11-24 2008-11-26 Teva Pharma Rasagiline orally disintegrating compositions
WO2006083608A1 (en) * 2005-02-02 2006-08-10 Teva Pharmaceutical Industries, Ltd. Process for producing polypeptide mixtures using hydrogenolysis
ES2420404T3 (es) * 2005-02-17 2013-08-23 Teva Pharmaceutical Industries Ltd. Terapia de combinación con acetato de glatiramero y rasagilina para el tratamiento de esclerosis múltiple
MX2007010233A (es) 2005-02-23 2007-11-07 Teva Pharma Formulaciones de rasagilina de uniformidad de contenido mejorada.
WO2007061717A2 (en) * 2005-11-17 2007-05-31 Teva Pharmaceutical Industries, Ltd. Methods for isolating propargylated aminoindans
US7572834B1 (en) 2005-12-06 2009-08-11 Teva Pharmaceutical Industries, Ltd. Rasagiline formulations and processes for their preparation
WO2007098264A2 (en) * 2006-02-21 2007-08-30 Teva Pharmaceutical Industries, Ltd. Use of rasagiline for the treatment of multiple system atrophy
JP5769923B2 (ja) * 2006-04-03 2015-08-26 テバ ファーマシューティカル インダストリーズ リミティド レストレスレッグス症候群の治療のためのラサギリンの使用
EP1892233A1 (de) 2006-08-18 2008-02-27 Ratiopharm GmbH Neue Salze des Wirkstoffs Rasagilin
PL2101569T3 (pl) * 2006-12-14 2012-03-30 Teva Pharma Stała, krystaliczna zasada rasagaliny
US7547806B2 (en) * 2006-12-14 2009-06-16 Teva Pharmaceutical Industries, Ltd. Tannate salt of rasagiline
EP1987816A1 (de) * 2007-04-30 2008-11-05 Ratiopharm GmbH Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff
AU2008296908B2 (en) * 2007-09-05 2014-01-09 Teva Pharmaceutical Industries, Ltd. Method of treating glaucoma using rasagiline
US8188149B2 (en) * 2007-09-17 2012-05-29 Teva Pharmaceutical Industries, Ltd. Use of R(+)-N-propargy1-1-aminoindan to treat or prevent hearing loss
BRPI0905680A2 (pt) * 2008-01-11 2015-07-07 Teva Pharma "composição farmacêutica de uma composição farmacêutica"
EP2271612B1 (en) * 2008-03-31 2016-08-10 Actavis Group PTC EHF Rasagiline mesylate particles and process for the preparation thereof
WO2009151594A1 (en) * 2008-06-10 2009-12-17 Teva Pharmaceutical Industries, Ltd. Rasagiline soft gelatin capsules
AU2009258151A1 (en) * 2008-06-13 2009-12-17 Teva Pharmaceutical Industries, Ltd. Rasagiline for Parkinson's disease modification
US7968749B2 (en) 2008-06-19 2011-06-28 Teva Pharmaceutical Industries, Ltd. Process for preparing and drying solid rasagiline base
CA2727021A1 (en) * 2008-06-19 2009-12-23 Teva Pharmaceutical Industries Ltd. Process for purifying rasagiline base
EP2358658A4 (en) * 2008-11-20 2012-11-14 Reddys Lab Ltd Dr PREPARATION OF RASAGILIN AND ITS SALTS
DE102008064061A1 (de) 2008-12-19 2010-06-24 Ratiopharm Gmbh Feste Zusammensetzung mit dem Wirkstoff Rasagilin
US20100189791A1 (en) * 2009-01-23 2010-07-29 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline malate formulation
KR20110130410A (ko) 2009-03-05 2011-12-05 산도즈 아게 라사길린 메실레이트를 함유하는 제약 조성물
WO2010111264A2 (en) * 2009-03-24 2010-09-30 Dr. Reddy's Laboratories Ltd. Rasagiline formulations
DK2451771T3 (da) 2009-07-09 2014-09-08 Ratiopharm Gmbh Salte af rasagilin og farmaceutiske fremstillingsmåder heraf
US8741962B2 (en) * 2009-11-26 2014-06-03 Usv Limited Process for preparation of Rasagiline and salts thereof
US20120321896A1 (en) * 2010-02-01 2012-12-20 Kuppuswamy Nagarajan Rasagiline mesylate having large particle size and a process for preparation thereof
CN104876937B (zh) * 2010-02-12 2017-07-28 辉瑞公司 8‑氟‑2‑{4‑[(甲氨基)甲基]苯基}‑1,3,4,5‑四氢‑6H‑氮杂*并[5,4,3‑cd]吲哚‑6‑酮的马来酸盐、其药物组合物及其用途
ES2608782T3 (es) 2010-04-30 2017-04-17 Teikoku Pharma Usa, Inc. Composiciones transdérmicas de propinilaminoindano
EP2389927A1 (en) 2010-05-30 2011-11-30 Abdi Ibrahim Ilac Sanayi ve Ticaret Anonim Sirketi Pharmaceutical formulations of rasagiline
EP2603212A4 (en) 2010-07-27 2014-01-08 Teva Pharma USE OF RASAGILINE FOR THE TREATMENT OF SMOKING DISORDER
JP2013537530A (ja) 2010-07-27 2013-10-03 テバ ファーマシューティカル インダストリーズ リミティド ラサギリンシトレートの分散物
KR101853082B1 (ko) 2011-03-24 2018-04-27 테이코쿠 팔마 유에스에이, 인코포레이티드 활성제층 및 활성제 변환층을 포함하는 경피 조성물
WO2012153349A2 (en) 2011-05-04 2012-11-15 Cadila Healthcare Limited Rasagiline and its pharmaceutically acceptable salts
CA2851276A1 (en) 2011-10-10 2013-04-18 Teva Pharmaceutical Industries Ltd. R(+)-n-formyl-propargyl-aminoindan
CA2851433A1 (en) 2011-10-10 2013-04-18 Teva Pharmaceutical Industries Ltd. R(+)-n-methyl-propargyl-aminoindan
EP2776020B1 (en) 2011-11-09 2019-09-11 Teikoku Seiyaku Co., Ltd. Methods for the treatment of skin neoplasms
EP2610239A1 (en) 2012-01-02 2013-07-03 Dr. Reddy's Laboratories Ltd. Preparation Of Rasagiline Hemitartrate
WO2013139387A1 (en) 2012-03-21 2013-09-26 Synthon Bv Stabilized pharmaceutical compositions comprising rasagiline salts
WO2014028868A1 (en) 2012-08-17 2014-02-20 Teva Pharmaceutical Industries Ltd. Parenteral formulation of rasagiline
AU2013338243B2 (en) 2012-11-02 2016-09-29 Teikoku Seiyaku Co., Ltd. Propynylaminoindan transdermal compositions
NZ630427A (en) 2013-03-14 2017-06-30 Teva Pharma Crystals of laquinimod sodium and improved process for the manufacture thereof
CA3106928C (en) 2016-11-10 2022-10-11 Medisca Pharmaceutique Inc. Pharmaceutical compounding methods and systems

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3513249A (en) 1968-12-24 1970-05-19 Ideal Ind Explosion connector with improved insulating means
GB8914804D0 (en) * 1989-06-28 1989-08-16 Glaxo Group Ltd Process
US5744500A (en) 1990-01-03 1998-04-28 Teva Pharmaceutical Industries, Ltd. Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
IL92952A (en) 1990-01-03 1994-06-24 Teva Pharma R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them
US5444095A (en) 1991-04-04 1995-08-22 University Of Toronto, Innovations Foundation Use of deprenyl to rescue damaged nerve cells
US5767164A (en) 1991-04-04 1998-06-16 Innovations Foundation Use of deprenyl to rescue damaged nerve cells
US5844003A (en) 1991-04-04 1998-12-01 Innovations Foundation Use of deprenyl compounds to maintain, prevent loss, or recover nerve cell function
IL99759A (en) 1991-10-16 1997-06-10 Teva Pharma Mono-fluorinated derivatives of n-propargyl-1-aminoindan, their preparation and pharmaceutical compositions containing them
IL111240A (en) 1993-10-18 2001-10-31 Teva Pharma Salts of r(+) - enantiomers of n- propargyl-1-aminoindan and pharmaceutical compositions comprising them
DE69535315T2 (de) 1994-01-10 2007-06-28 Teva Pharmaceutical Industries Ltd. 1-aminoindanderivate und zusammensetzungen hiervon
IL115357A (en) 1995-09-20 2000-01-31 Teva Pharma Stable compositions containing N-propargyl-1-aminoindan and polyhydric alcohols
IL118836A (en) 1996-07-11 2001-01-11 Teva Pharma Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan
HU229507B1 (en) 1996-12-18 2014-01-28 Technion Res & Dev Foundation 1,2,3,4-tetrahydro-amino-naphtalenyl- and aminoindan derivatives and pharmaceutical compositions comprising them
WO1999037293A2 (en) 1998-01-27 1999-07-29 Thomas Thomas N Use of an mao-a or mao-b inhibitor for the treatment of vascular disorders
US7766013B2 (en) * 2001-06-05 2010-08-03 Alexza Pharmaceuticals, Inc. Aerosol generating method and device
WO2003011255A1 (en) 2001-07-04 2003-02-13 Sun Pharmaceutical Industries Limited Gastric retention controlled drug delivery system
US20040052843A1 (en) 2001-12-24 2004-03-18 Lerner E. Itzhak Controlled release dosage forms
AU2003219913A1 (en) 2002-02-27 2003-09-09 Teva Pharmaceutical Industries, Ltd. Propargylamino indan derivatives and propargylamino tetralin derivatives as brain-selective mao inhibitors
US20040010038A1 (en) 2002-02-27 2004-01-15 Eran Blaugrund Propargylamino indan derivatives and propargylamino tetralin derivatives as brain-selective MAO inhibitors
EP2526944B1 (en) 2002-11-15 2016-06-01 Teva Pharmaceutical Industries Limited Use of rasagiline with or without riluzole to treat amyotrophic lateral sclerosis
WO2004112799A1 (en) * 2003-06-13 2004-12-29 Chrysalis Technologies Incorporated Methods and apparatus for producing nanoscale particles
US20050026979A1 (en) * 2003-07-31 2005-02-03 Maha Ghazzi Methods for treating inflammation and inflammation-associated diseases with a statin and ether
US7735024B2 (en) * 2003-10-29 2010-06-08 Intel Corporation Methods and apparatus to provide a handheld pointer-based user interface
JP2008507586A (ja) 2004-07-26 2008-03-13 テバ ファーマシューティカル インダストリーズ リミティド ラサグリンを含む、医薬投与剤
ZA200704917B (en) 2004-11-24 2008-11-26 Teva Pharma Rasagiline orally disintegrating compositions
MX2007006199A (es) 2004-11-24 2007-07-13 Teva Pharma Composiciones de desintegracion oral de rasagilina.
MX2007010233A (es) 2005-02-23 2007-11-07 Teva Pharma Formulaciones de rasagilina de uniformidad de contenido mejorada.
WO2007061717A2 (en) 2005-11-17 2007-05-31 Teva Pharmaceutical Industries, Ltd. Methods for isolating propargylated aminoindans
US7572834B1 (en) 2005-12-06 2009-08-11 Teva Pharmaceutical Industries, Ltd. Rasagiline formulations and processes for their preparation
WO2007098264A2 (en) 2006-02-21 2007-08-30 Teva Pharmaceutical Industries, Ltd. Use of rasagiline for the treatment of multiple system atrophy
JP5769923B2 (ja) 2006-04-03 2015-08-26 テバ ファーマシューティカル インダストリーズ リミティド レストレスレッグス症候群の治療のためのラサギリンの使用
EP1892233A1 (de) 2006-08-18 2008-02-27 Ratiopharm GmbH Neue Salze des Wirkstoffs Rasagilin
PL2101569T3 (pl) 2006-12-14 2012-03-30 Teva Pharma Stała, krystaliczna zasada rasagaliny
US7547806B2 (en) 2006-12-14 2009-06-16 Teva Pharmaceutical Industries, Ltd. Tannate salt of rasagiline
EP1987816A1 (de) 2007-04-30 2008-11-05 Ratiopharm GmbH Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff
BRPI0905680A2 (pt) 2008-01-11 2015-07-07 Teva Pharma "composição farmacêutica de uma composição farmacêutica"

Also Published As

Publication number Publication date
AU2006216696B2 (en) 2011-08-18
HK1103366A1 (zh) 2007-12-21
NZ560660A (en) 2010-11-26
ES2586412T3 (es) 2016-10-14
EP1848402B1 (en) 2016-05-11
EP1848402B2 (en) 2019-02-20
US7815942B2 (en) 2010-10-19
KR20070111534A (ko) 2007-11-21
ES2586412T5 (es) 2019-05-16
JP2008531572A (ja) 2008-08-14
WO2006091657A1 (en) 2006-08-31
JP2013139452A (ja) 2013-07-18
CA2600011A1 (en) 2006-08-31
AU2006216696A1 (en) 2006-08-31
EP1848402A4 (en) 2012-01-18
MX2007010233A (es) 2007-11-07
JP5738509B2 (ja) 2015-06-24
KR20170023211A (ko) 2017-03-02
KR20140103356A (ko) 2014-08-26
RU2404746C2 (ru) 2010-11-27
IL244802A0 (en) 2016-04-21
IL184033A0 (en) 2007-10-31
RU2007135169A (ru) 2009-03-27
IL244802A (en) 2016-08-31
KR20130129300A (ko) 2013-11-27
CA2901244A1 (en) 2006-08-31
CA2600011C (en) 2015-11-10
KR20180026580A (ko) 2018-03-12
EP1848402A1 (en) 2007-10-31
NO20074823L (no) 2007-11-16
BRPI0608209A2 (pt) 2010-11-09
US20060188581A1 (en) 2006-08-24

Similar Documents

Publication Publication Date Title
IS8669A (is) Rasagilínlyfjablöndur sem einsleitni innihaldsefna hefur verið endurbætt í
HK1256288A1 (zh) 自緩衝蛋白製劑
TWI348710B (en) Conductive compositions and processes for use in the manufacture of semiconductor devices
EP1941901A4 (en) TOPICALLY APPLIED FORMULATION AND ITS PREPARATION METHOD AND USES
EP1881839A4 (en) COMPOSITIONS FROM BACUCHIOL AND METHOD FOR THE PRODUCTION THEREOF
ATE482618T1 (de) Wirkstoffkombinationen
EP1883389A4 (en) LOW IRRITANT COMPOSITIONS AND METHODS OF MAKING SAME
ATE484194T1 (de) Wirkstoffkombinationen
EP1876157A4 (en) SEMICONDUCTOR PORCELAIN COMPOSITION AND METHOD FOR MANUFACTURING THE SAME
ATE444748T1 (de) 1-ä(3-hydroxy-adamant-1-ylamino)-acetylü- pyrrolidin-2(s)-carbonitril-formulierung mit modifizierter freisetzung
EP1889304A4 (en) COMPOSITIONS AND THERMOELECTRIC PROCESS
TWI370809B (en) Polyacene and semiconductor formulation
PT1883665T (pt) Composições polilactídeo e usos das mesmas
EP1851335A4 (en) COMPOSITIONS AND METHODS FOR USE OF STANDARDIZED MIXTURES
HK1198914A1 (en) Novel dosage formulation
IL184111A0 (en) Prostaglandin-containing compositions and methods for enhancing the stability thereof
IL184834A0 (en) Compositions and methods for the manufacture thereof
ZA200801896B (en) Slow-release composition, method for the preparation thereof, and use of the same
ZA200802646B (en) Formulation of AICA Riboside
EP1848438A4 (en) DIAMINOPHENOTHIAZINE COMPOSITIONS AND THEIR USE
GB0504924D0 (en) Perfume compositions
IL185723A0 (en) Controlled release pharmaceutical compositions of liothyronine and methods of making and using the same
GB0723011D0 (en) Fragrance compositions
GB0505702D0 (en) Perfume compositions
EP1888099A4 (en) HYDRATABLE COMPOSITIONS BASED ON KERATIN